Intravenous lidocaine vs. NSAIDs for migraine attack in the ED: a prospective, randomized, double-blind study

2021 ◽  
Author(s):  
Sultan Tuna Akgol Gur ◽  
Elif Oral Ahiskalioglu ◽  
Muhammed Enes Aydin ◽  
Abdullah Osman Kocak ◽  
Pelin Aydin ◽  
...  
Keyword(s):  
Migraine Attack ◽  
Blind Study ◽  
Double Blind Study ◽  
Intravenous Lidocaine ◽  
Double Blind

Treatment of Acute Migraine Attack With Diclofenac Sodium: A Double-Blind Study

1992 ◽  
Vol 32 (2) ◽  
pp. 98-100 ◽  
Author(s):  
George N. Karachalios ◽  
Adroniki Fotiadou ◽  
Nickolaos Chrisikos ◽  
Alexandros Karabetsos ◽  
Kyriakos Kehagioglou
Keyword(s):  
Migraine Attack ◽  
Diclofenac Sodium ◽  
Blind Study ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind ◽  
Acute Migraine Attack

Postoperative analgesic efficacy of perioperative intravenous lidocaine infusion in patients undergoing septorhinoplasty: a prospective, randomized, double-blind study

2020 ◽  
Vol 277 (4) ◽  
pp. 1095-1100 ◽  
Author(s):  
İrem Ates ◽  
Muhammed Enes Aydin ◽  
Ali Ahiskalioglu ◽  
Elif Oral Ahiskalioglu ◽  
Zulkuf Kaya ◽  
...  
Keyword(s):  
Analgesic Efficacy ◽  
Blind Study ◽  
Double Blind Study ◽  
Intravenous Lidocaine ◽  
Double Blind

Effervescent Metoclopramide and Aspirin (Migravess) Versus Effervescent Aspirin or Placebo for Migraine Attacks: A Double-Blind Study

Cephalalgia ◽  
1984 ◽  
Vol 4 (2) ◽  
pp. 107-111 ◽  
Author(s):  
Peer Tfelt-Hansen ◽  
Jes Olesen
Keyword(s):  
Migraine Attack ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Significant Difference ◽  
Better Than

Aspirin 650 mg and metoclopramide 10 mg in an effervescent preparation (Migravess(r)) were compared with effervescent aspirin 650 mg (Alka-Seltzer(r)) and placebo for common migraine attacks with a double-blind cross-over design. One hundred and eighteen patients with common migraine were entered. Eighty-five patients completed all three forms of treatment, eleven completed two, and six completed one. Medicine was taken when patients were sure they had a migraine attack and not just interval headache. After each form of treatment, they mailed a report form to the investigators. Additional medication was allowed after 2 h and was taken for 79/95 placebo treated attacks, 63/92 Migravess treated attacks, and 51/86 aspirin treated attacks (p < 0.01). Aspirin was significantly better than placebo for pain but not quite significant for nausea. Migravess(r) was significantly better than placebo for pain and for nausea. There was no significant difference between aspirin and Migravess(r) with regard to analgesic effectiveness (p = 0.33) or to antinausea effect (p = 0.18).

Sign in / Sign up

Export Citation Format

Share Document